226 related articles for article (PubMed ID: 7700632)
1. Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma.
Corvi R; Savelyeva L; Breit S; Wenzel A; Handgretinger R; Barak J; Oren M; Amler L; Schwab M
Oncogene; 1995 Mar; 10(6):1081-6. PubMed ID: 7700632
[TBL] [Abstract][Full Text] [Related]
2. Cytogenetic evolution of MYCN and MDM2 amplification in the neuroblastoma LS tumour and its cell line.
Corvi R; Savelyeva L; Amler L; Handgretinger R; Schwab M
Eur J Cancer; 1995; 31A(4):520-3. PubMed ID: 7576957
[TBL] [Abstract][Full Text] [Related]
3. Amplified MYCN in human neuroblastoma: paradigm for the translation of molecular genetics to clinical oncology.
Schwab M
Ann N Y Acad Sci; 2002 Jun; 963():63-73. PubMed ID: 12095930
[TBL] [Abstract][Full Text] [Related]
4. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
[TBL] [Abstract][Full Text] [Related]
5. p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells.
Tweddle DA; Malcolm AJ; Cole M; Pearson AD; Lunec J
Am J Pathol; 2001 Jun; 158(6):2067-77. PubMed ID: 11395384
[TBL] [Abstract][Full Text] [Related]
6. MYCN is retained in single copy at chromosome 2 band p23-24 during amplification in human neuroblastoma cells.
Corvi R; Amler LC; Savelyeva L; Gehring M; Schwab M
Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5523-7. PubMed ID: 8202521
[TBL] [Abstract][Full Text] [Related]
7. Where pathology meets molecular biology: N-myc amplification in human neuroblastoma as a paradigm for the clinical use of an oncogene alteration.
Schwab M
Verh Dtsch Ges Pathol; 1994; 78():26-33. PubMed ID: 7533996
[TBL] [Abstract][Full Text] [Related]
8. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
[TBL] [Abstract][Full Text] [Related]
9. Caspase-9 and Apaf-1 are expressed and functionally active in human neuroblastoma tumor cell lines with 1p36 LOH and amplified MYCN.
Teitz T; Wei T; Liu D; Valentine V; Valentine M; Grenet J; Lahti JM; Kidd VJ
Oncogene; 2002 Mar; 21(12):1848-58. PubMed ID: 11896617
[TBL] [Abstract][Full Text] [Related]
10. Detection of MYCN amplification in three neuroblastoma cell lines by non-radioactive chromosomal in situ hybridization.
McRobert TL; Rudduck C; Kees UR; Garson OM
Cancer Genet Cytogenet; 1992 Apr; 59(2):128-34. PubMed ID: 1581879
[TBL] [Abstract][Full Text] [Related]
11. The p53 pathway and its inactivation in neuroblastoma.
Tweddle DA; Pearson AD; Haber M; Norris MD; Xue C; Flemming C; Lunec J
Cancer Lett; 2003 Jul; 197(1-2):93-8. PubMed ID: 12880966
[TBL] [Abstract][Full Text] [Related]
12. p53 is a direct transcriptional target of MYCN in neuroblastoma.
Chen L; Iraci N; Gherardi S; Gamble LD; Wood KM; Perini G; Lunec J; Tweddle DA
Cancer Res; 2010 Feb; 70(4):1377-88. PubMed ID: 20145147
[TBL] [Abstract][Full Text] [Related]
13. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma.
He J; Gu L; Zhang H; Zhou M
Cell Cycle; 2011 Sep; 10(17):2994-3002. PubMed ID: 21862876
[TBL] [Abstract][Full Text] [Related]
14. Amplification of a gene encoding a p53-associated protein in human sarcomas.
Oliner JD; Kinzler KW; Meltzer PS; George DL; Vogelstein B
Nature; 1992 Jul; 358(6381):80-3. PubMed ID: 1614537
[TBL] [Abstract][Full Text] [Related]
15. Amplification of a DEAD box gene (DDX1) with the MYCN gene in neuroblastomas as a result of cosegregation of sequences flanking the MYCN locus.
Noguchi T; Akiyama K; Yokoyama M; Kanda N; Matsunaga T; Nishi Y
Genes Chromosomes Cancer; 1996 Feb; 15(2):129-33. PubMed ID: 8834177
[TBL] [Abstract][Full Text] [Related]
16. MYCN amplification and 17q in neuroblastoma: evidence for structural association.
O'Neill S; Ekstrom L; Lastowska M; Roberts P; Brodeur GM; Kees UR; Schwab M; Bown N
Genes Chromosomes Cancer; 2001 Jan; 30(1):87-90. PubMed ID: 11107180
[TBL] [Abstract][Full Text] [Related]
17. MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification.
Valent A; Le Roux G; Barrois M; Terrier-Lacombe MJ; Valteau-Couanet D; Léon B; Spengler B; Lenoir G; Bénard J; Bernheim A
J Pathol; 2002 Dec; 198(4):495-501. PubMed ID: 12434419
[TBL] [Abstract][Full Text] [Related]
18. Co-amplification of MYCN and a DEAD box gene (DDX1) in primary neuroblastoma.
Squire JA; Thorner PS; Weitzman S; Maggi JD; Dirks P; Doyle J; Hale M; Godbout R
Oncogene; 1995 Apr; 10(7):1417-22. PubMed ID: 7731693
[TBL] [Abstract][Full Text] [Related]
19. The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma.
Slack A; Chen Z; Tonelli R; Pule M; Hunt L; Pession A; Shohet JM
Proc Natl Acad Sci U S A; 2005 Jan; 102(3):731-6. PubMed ID: 15644444
[TBL] [Abstract][Full Text] [Related]
20. [Amplification of N-myc in neuroblastoma: paradigm for clinical use of an oncogene alteration].
Schwab M
Klin Padiatr; 1990; 202(4):197-201. PubMed ID: 2203936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
